BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 20603245)

  • 21. Multicenter feasibility study of combination therapy with fluorouracil, leucovorin and paclitaxel (FLTAX) for peritoneal disseminated gastric cancer with massive ascites or inadequate oral intake.
    Iwasa S; Goto M; Yasui H; Nishina T; Takahari D; Nakayama N; Taira K; Kusaba H; Fuse N; Hironaka S; Shimada Y; Nakajima TE
    Jpn J Clin Oncol; 2012 Sep; 42(9):787-93. PubMed ID: 22782960
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase I study of bi-weekly docetaxel for recurrent or advanced gastric cancer patients whose disease progressed by prior chemotherapy.
    Kimura Y; Yano H; Taniguchi H; Iwazawa T; Danno K; Kagara N; Kanoh T; Ohnishi T; Tono T; Nakano Y; Monden T; Imaoka S
    Jpn J Clin Oncol; 2011 Jun; 41(6):747-51. PubMed ID: 21498408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker.
    Hirakawa M; Sato Y; Ohnuma H; Takayama T; Sagawa T; Nobuoka T; Harada K; Miyamoto H; Sato Y; Takahashi Y; Katsuki S; Hirayama M; Takahashi M; Ono M; Maeda M; Takada K; Hayashi T; Sato T; Miyanishi K; Takimoto R; Kobune M; Hirata K; Kato J
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):789-97. PubMed ID: 23338051
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I study of a combination of s-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer.
    Ueda Y; Yamagishi H; Ichikawa D; Morii J; Koizumi K; Kakihara N; Shimotsuma M; Takenaka A; Yamashita T; Kurioka H; Nishiyama M; Morita S; Nakamura K; Sakamoto J
    Oncology; 2005; 69(3):261-8. PubMed ID: 16138002
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preoperative systemic and intraperitoneal chemotherapy consisting of S-1, cisplatin and docetaxel in patients with marginally resectable gastric cancer.
    Kurokawa Y; Hamakawa T; Miyazaki Y; Takahashi T; Yamasaki M; Miyata H; Nakajima K; Takiguchi S; Mori M; Doki Y
    Anticancer Res; 2015 Apr; 35(4):2223-8. PubMed ID: 25862882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer.
    Takayama T; Sato Y; Sagawa T; Okamoto T; Nagashima H; Takahashi Y; Ohnuma H; Kuroiwa G; Miyanishi K; Takimoto R; Matsunaga T; Kato J; Yamaguchi K; Hirata K; Niitsu Y
    Br J Cancer; 2007 Oct; 97(7):851-6. PubMed ID: 17848958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I trial of weekly docetaxel with a 4-weekly cisplatin administration in patients with advanced gastric carcinoma.
    Polyzos A; Syrigos K; Stergiou J; Panopoulos C; Potamianou A; Vamvakas L; Georgoulias V
    Cancer Chemother Pharmacol; 2005 May; 55(5):466-70. PubMed ID: 15660272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
    Koizumi W; Narahara H; Hara T; Takagane A; Akiya T; Takagi M; Miyashita K; Nishizaki T; Kobayashi O; Takiyama W; Toh Y; Nagaie T; Takagi S; Yamamura Y; Yanaoka K; Orita H; Takeuchi M
    Lancet Oncol; 2008 Mar; 9(3):215-21. PubMed ID: 18282805
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I study of oral S-1 plus Cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.
    Kaira K; Sunaga N; Yanagitani N; Kawata T; Utsugi M; Shimizu K; Ebara T; Kawamura H; Nonaka T; Ishikawa H; Sakurai H; Suga T; Hara K; Hisada T; Ishizuka T; Nakano T; Mori M
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):109-14. PubMed ID: 18929446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer.
    Lee JL; Kang HJ; Kang YK; Ryu MH; Chang HM; Kim TW; Sohn HJ; Kim H; Lee JS
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):837-45. PubMed ID: 17579864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I study of combination therapy of the oral fluorinated pyrimidine compound S-1 with low-dose cisplatin twice-a-week administration (JFMC27-9902 Step2) in patients with advanced gastric cancer using a continual reassessment method.
    Morita S; Nakata B; Tsuji A; Mitachi Y; Shirasaka T; Saji S; Ohashi Y; Sakamoto J; Hirakawa K
    Jpn J Clin Oncol; 2007 Dec; 37(12):924-9. PubMed ID: 18211983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I/II study of S-1 plus cisplatin in patients with advanced gastric cancer: 2-week S-1 administration regimen.
    Sato Y; Kondo H; Honda K; Takahari D; Sumiyoshi T; Tsuji Y; Yoshizaki N; Niitsu Y
    Int J Clin Oncol; 2005 Feb; 10(1):40-4. PubMed ID: 15729600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer.
    Lee SJ; Cho SH; Yoon JY; Hwang JE; Bae WK; Shim HJ; Chung IJ
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):159-66. PubMed ID: 19479256
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Docetaxel + 5-fluorouracil + cisplatin 3-day combination chemotherapy as a first-line treatment in patients with unresectable gastric cancer.
    Oh DY; Kim TY; Kwon JH; Lee JJ; Joh Y; Kim DW; Kim TY; Heo DS; Bang YJ; Kim NK
    Jpn J Clin Oncol; 2005 Jul; 35(7):380-5. PubMed ID: 15976069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I/II Study of S-1 Plus Cisplatin Alternating With S-1 Plus Docetaxel in Patients With Advanced Gastric Cancer.
    Hosokawa A; Ando T; Ogawa K; Ueda A; Yoshita H; Mihara H; Fujinami H; Kajiura S; Yabushita K; Horikawa N; Kobayashi Y; Yoshioka A; Origasa H; Sugiyama T
    Am J Clin Oncol; 2018 Oct; 41(10):977-981. PubMed ID: 28930775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I dose-escalating study of 24-h continuous infusion of 5-fluorouracil in combination with weekly docetaxel and cisplatin in patients with advanced gastric cancer.
    Wang B; Zhang W; Hong X; Guo Y; Li J
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):213-8. PubMed ID: 18343924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma.
    Ajani JA; Faust J; Ikeda K; Yao JC; Anbe H; Carr KL; Houghton M; Urrea P
    J Clin Oncol; 2005 Oct; 23(28):6957-65. PubMed ID: 16145066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer.
    Park KW; Ahn JS; Park YS; Lee J; Kang JH; Park JO; Lim HY; Im YH; Kang WK; Park K; Lee SI
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):17-21. PubMed ID: 16721549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
    Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I study of combination chemotherapy consisting of paclitaxel, cisplatin, and S-1 in patients with unresectable gastric cancer (KOGC-02).
    Takahashi T; Saikawa Y; Fukuda K; Funakoshi S; Kawakubo H; Takeuchi H; Takaishi H; Kitagawa Y
    Anticancer Res; 2012 Dec; 32(12):5401-6. PubMed ID: 23225443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.